Third Wave Begins Clinical Trial For HPV Products
The Capital Times
Madison-based Third Wave Technologies Inc. announced that clinical trials have begun for its two human papillomavirus (HPV) products.
The genetic technology company said it continues to anticipate submitting the applications for approval of those products to the U.S. Food and Drug Administration next year. .Read Article |
